News & updates
Oncology research breakthroughs and CancerFax milestones — all in one place.
8 items
June
Incisionless Brain Treatment Offers New Hope for Parkinson's Patients with Medication-Resistant Tremor
A groundbreaking technology called MRgFUS (magnetic resonance-guided focused ultrasound) is offering relief for Parkinson's patients with medication-resistant tremor. Unlike traditional brain surgery, this incisionless procedure uses focused ultrasound to target tremor-causing brain circuits without implants or long recovery. Available at select leading medical centers worldwide, MRgFUS shows 50–80% tremor reduction in carefully selected patients, often with improvement visible immediately after treatment.
A New Drug May Double Survival in Pancreatic Cancer: What Patients Need to Know
Pancreatic cancer has long been one of oncology's most resistant frontiers. At ASCO 2026, results from the phase 3 RASolute 302 trial changed that narrative. The oral drug daraxonrasib nearly doubled survival in patients with previously treated metastatic pancreatic cancer, achieving a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. Oncologists are calling it transformative. Here is what patients and families need to know.
CARsgen's Claudin 18.2 CAR-T (Satri-cel) Moves Closer to Approval in China
CARsgen's satricabtagene autoleucel (satri-cel) is under priority review by China's NMPA for advanced gastric and gastroesophageal junction cancer, and it could be the world's first CAR-T therapy approved for a solid tumor. Here's what the data shows and what it means for patients.
CancerFax Visits Shenzhen Children's Hospital BMT Center and Meets Prof. Liu Sixi
CancerFax Founder Sandeep Kumar Wamne and Co-Founder Nishant Mittal visited the Bone Marrow Transplant Center at Shenzhen Children's Hospital, meeting gene therapy specialist Prof. Liu Sixi and HemoGen leadership to understand advanced thalassemia care first-hand.
May
CancerFax Partners with Global Oncology to Access China's Cancer Trial Network
CancerFax has entered into a working collaboration with Global Oncology, a leading clinical research organization in China. Direct access to one of the most active cancer trial ecosystems in the world — for patients who need it most.
CancerFax Team Visits Chula Cell and Gene Therapy Center in Bangkok
A CancerFax-led delegation visited the Chula Cell and Gene Therapy Center in Bangkok to learn first-hand about the progress in gene therapy for thalassemia — and what it means for patients and families waiting for better options.
January
VectorGene Biotech, Parent of CancerFax, Partners with the Chinese National Human Genome Center, Beijing
VectorGene Biotech Limited, the Hong Kong based parent company of CancerFax, has entered into a collaboration with the Chinese National Human Genome Center, Beijing (CHGB) and its translational arm IDTRI to bring advanced genomic testing, cell and gene therapy, and technology transfer programs to international hospitals, laboratories, and research partners.
CancerFax Establishes Strategic Partnership with RoyalLee Cancer Hospital in Guangzhou
RoyalLee Cancer Hospital in Guangzhou offers a focused range of advanced minimally invasive treatments for complex cancer cases. These include Yttrium-90 selective internal radiation therapy for liver tumors, argon-helium cryoablation for targeted tumor destruction using extreme cold, and nanoknife irreversible electroporation for cancers near critical structures where conventional ablation carries higher risk. Each treatment requires individual eligibility assessment based on cancer type, stage, tumor location, and overall patient condition.